Zacks Research Equities Analysts Reduce Earnings Estimates for Agilent Technologies, Inc. (NYSE:A)

Agilent Technologies, Inc. (NYSE:A) – Analysts at Zacks Research dropped their FY2025 earnings per share (EPS) estimates for shares of Agilent Technologies in a research note issued to investors on Wednesday, July 31st. Zacks Research analyst S. Mete now forecasts that the medical research company will post earnings per share of $5.70 for the year, down from their previous forecast of $5.71. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.24 per share. Zacks Research also issued estimates for Agilent Technologies’ Q3 2026 earnings at $1.63 EPS and FY2026 earnings at $6.35 EPS.

Several other research analysts also recently commented on the company. TD Cowen reiterated a “buy” rating and set a $153.00 target price on shares of Agilent Technologies in a research note on Monday. JPMorgan Chase & Co. dropped their target price on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a research report on Thursday, May 30th. Robert W. Baird reduced their price objective on Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating on the stock in a research note on Thursday, May 30th. Jefferies Financial Group reaffirmed a “hold” rating and set a $135.00 target price (down previously from $152.00) on shares of Agilent Technologies in a research note on Monday, June 3rd. Finally, Evercore ISI raised their price objective on Agilent Technologies from $126.00 to $130.00 and gave the company an “in-line” rating in a report on Tuesday, July 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.06.

Agilent Technologies Stock Up 1.0 %

A stock opened at $142.86 on Friday. The business has a 50-day moving average of $133.55 and a 200-day moving average of $137.81. Agilent Technologies has a fifty-two week low of $96.80 and a fifty-two week high of $155.35. The stock has a market capitalization of $41.68 billion, a P/E ratio of 33.77, a P/E/G ratio of 4.81 and a beta of 1.05. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.15 and a quick ratio of 1.64.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, May 29th. The medical research company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.19 by $0.03. The company had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The business’s revenue for the quarter was down 8.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.27 earnings per share.

Institutional Investors Weigh In On Agilent Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Crewe Advisors LLC lifted its position in shares of Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after buying an additional 101 shares in the last quarter. Livelsberger Financial Advisory bought a new stake in shares of Agilent Technologies during the 4th quarter valued at $26,000. MV Capital Management Inc. lifted its stake in shares of Agilent Technologies by 120.7% during the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock valued at $27,000 after buying an additional 105 shares in the last quarter. VisionPoint Advisory Group LLC purchased a new stake in Agilent Technologies in the 4th quarter worth $29,000. Finally, Ridgewood Investments LLC bought a new stake in Agilent Technologies during the second quarter valued at about $29,000.

Insider Transactions at Agilent Technologies

In other news, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the completion of the sale, the senior vice president now directly owns 49,486 shares in the company, valued at approximately $6,595,494.08. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the transaction, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at $6,595,494.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $140.00, for a total value of $274,120.00. Following the completion of the sale, the chief executive officer now directly owns 26,076 shares of the company’s stock, valued at approximately $3,650,640. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,916 shares of company stock valued at $2,527,860.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 24th. Stockholders of record on Tuesday, July 2nd were given a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a dividend yield of 0.66%. The ex-dividend date was Tuesday, July 2nd. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.22%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.